Complete response to alemtuzumab in a patient with B prolymphocytic leukemia [7]

American Journal of Hematology

Volumn 82, Issue 5, 2007, Pages 417-

  Chaar, Bassem T ^a   Petruska, Paul J ^b  

^a Bothwell Regional Health Center   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL EXAMINATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, PROLYMPHOCYTIC; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 34247523269     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20843     Document Type: Letter

References (5)

1. Absi A, Hsi E, Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 2005;6:197-208.
2. Herold M, Spohn C, Schlag R, et al. Fludarabine/Cyclophosphamide chemotherapy for B-prolymphocytic leukemia. Blood 2003;102:675a.
3. Vartholomatos G, Tsiara S, Christou L, et al. Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 1999;102:94-98.
4. Perz J, Topaly J, Fruehauf S, et al. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocyte leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:149-151.
5. McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocyte leukemia. Leuk Lymphoma 2002;43:1007-1011.